Literature DB >> 30779602

Approaches for CNS delivery of drugs - nose to brain targeting of antiretroviral agents as a potential attempt for complete elimination of major reservoir site of HIV to aid AIDS treatment.

Shweta Gupta1, Rajesh Kesarla2, Abdelwahab Omri3.   

Abstract

INTRODUCTION: Human immune-deficiency virus (HIV) infection causing acquired immune-deficiency syndrome (AIDS) is one of the most life-threatening infections. The central nervous system (CNS) is reported to be the most important HIV reservoir site where the antiretroviral drugs are unable to reach. AREAS COVERED: This article includes the review about HIV infections, its pathogenesis, HIV infections in CNS, its consequences, current therapies, challenges associated with the existing therapies, approaches to overcome them, CNS delivery of drugs - barriers, transport routes, approaches for transporting drugs across the blood-brain barrier, nasal route of drug delivery, and nose to brain targeting of antiretroviral agents as a potential approach for complete cure of AIDS. EXPERT OPINION: Various approaches are exploited to enhance the drug delivery to the brain for various categories of drugs. However, very few have investigated on the delivery of antiretrovirals to the brain. Targeting antiretrovirals to CNS through oral/nasal routes along with oral/parenteral delivery of drug to the plasma can be a promising approach for an attempt to completely eradicate HIV reservoir and cure AIDS, after clinical trials. Further research is required to identify the exact location of the HIV reservoir in CNS and developing good animal models for evaluation of different newly developed formulations.

Entities:  

Keywords:  AIDS; BBB; CNS; HIV; bioavailability; brain; nanoparticles; nasal; targeting

Mesh:

Substances:

Year:  2019        PMID: 30779602     DOI: 10.1080/17425247.2019.1583206

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  6 in total

1.  Nanosized Cubosomal Thermogelling Dispersion Loaded with Saquinavir Mesylate to Improve Its Bioavailability: Preparation, Optimization, in vitro and in vivo Evaluation.

Authors:  Khaled M Hosny
Journal:  Int J Nanomedicine       Date:  2020-07-16

2.  Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders.

Authors:  Tiziana Latronico; Federica Rizzi; Annamaria Panniello; Valentino Laquintana; Ilaria Arduino; Nunzio Denora; Elisabetta Fanizza; Serafina Milella; Claudio M Mastroianni; Marinella Striccoli; Maria Lucia Curri; Grazia M Liuzzi; Nicoletta Depalo
Journal:  ACS Chem Neurosci       Date:  2021-11-02       Impact factor: 5.780

Review 3.  The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection.

Authors:  Anna Halling Folkmar Andersen; Martin Tolstrup
Journal:  Viruses       Date:  2020-04-07       Impact factor: 5.048

Review 4.  Microglial Cells: The Main HIV-1 Reservoir in the Brain.

Authors:  Clementine Wallet; Marco De Rovere; Jeanne Van Assche; Fadoua Daouad; Stéphane De Wit; Virginie Gautier; Patrick W G Mallon; Alessandro Marcello; Carine Van Lint; Olivier Rohr; Christian Schwartz
Journal:  Front Cell Infect Microbiol       Date:  2019-10-24       Impact factor: 5.293

Review 5.  A review of potential microbiome-gut-brain axis mediated neurocognitive conditions in persons living with HIV.

Authors:  Shannan Rich; Emily Klann; Vaughn Bryant; Veronica Richards; Akemi Wijayabahu; Kendall Bryant; Volker Mai; Robert Cook
Journal:  Brain Behav Immun Health       Date:  2020-11-02

Review 6.  Dendrimer-Based Drug Delivery Systems for Brain Targeting.

Authors:  Yuefei Zhu; Chunying Liu; Zhiqing Pang
Journal:  Biomolecules       Date:  2019-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.